FAS and retinal degeneration: While the use of ONL1204 for intravitreal injection presents a more viable route for clinical application compared to genetic manipulation of Fas inhibition, it is suggested that pharmacological inactivation of Fas might be most effective when integrated into a multi-therapy approach that targets various pathways contributing to retinal degeneration.